1. Samaan N.A., Maheshwari Y.K., Nader S., Hill C.S., Schultz P.N., Haynie T.P., Hickey R.C., Clark R.L., Goepfert H., Ibanez M.L., Litton C.E. Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J. Clin. Endocrinol. Metab. 56: 1131, 1983.
2. DeGroot L.J. Thyroid neoplasia. Endocrinology, 3rd edition. W.B. Saunders, Philadelphia, 1995, p. 834.
3. Lin J.D., Huang M.J., Huang B.Y., Huang H.S., Jeng L.B. Thyroid cancer treated in Chang Gung Memorial Hospital (Northern Taiwan), during the period: 1979–1992: Clinical presentation, pathological finding, analysis of prognostic variables and results of treatment. J. Surg. Oncol. 57: 244, 1994.
4. Beierwaltes W.H., Rabbani R., Dmuchowski C., Lloyd R.V., Eyre P., Mallette S. An analysis of “ablation of thyroid remnants” with I-131 in 511 patients from 1947–1984: experience at University of Michigan. J. Nucl. Med. 25: 1287, 1984.
5. Goolden A.W.G. The indications for ablating normal thyroid tissue with 131I in differentiated thyroid cancer. Clin. Endocrinol. (Oxf.) 23: 81, 1985.